Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orforglipron in obesity or overweight without diabetes
NCT06824051Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2025
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in obesity comparing Orforglipron with Placebo (2 arms). Primary endpoint: Percent Change from Baseline in Visceral Adipose Tissue at 36 weeks. Started Feb 2025; status: completed.
02
Drugs
orforglipron
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06824051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06824051.